ALM008
Bipolar Disorder
Phase 2Active
Key Facts
About Almatica Pharma
Almatica Pharma, a subsidiary of the global generics firm Alvogen, is a specialty CNS-focused pharmaceutical company developing novel treatments for psychiatric and neurological disorders. Founded in 2008 and headquartered in Pittsburgh, the company leverages a lean structure and end-to-end R&D capabilities to advance a pipeline of several drug candidates, primarily in mid-to-late-stage clinical development for depression and anxiety. As a private entity, it benefits from the commercial infrastructure and expertise of its parent company while targeting significant unmet needs in the mental health therapeutic area with innovative medicines and patient support programs.
View full company profileTherapeutic Areas
Other Bipolar Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Phase II |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| 4MT2001 | 4M Therapeutics | Pre-clinical |
| Bipolar Disorder Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| RAP-219 | Rapport Therapeutics | Discovery |